The choice of cloud or local storage, smart AI-led tracking and solar power to effectively eliminate power worries in most situations makes the Tapo C660 well worth consideration. There's no shortage ...

The move is set to align crypto execution with traditional wholesale markets, in a bid to enhance capital efficiency, risk management and institutional confidence. TP ICAP is transitioning its spot ...

The era of size inclusivity is seemingly over. Our critic traces the shift and hopes designers might learn from it. By Vanessa Friedman I know models have always been skinny, but it seems to me they ...

This article is part of Kotaku Deals, produced separately from the editorial team. We may earn a commission when you buy through links on the site. Almost everyone has that one mysterious corner of ...

There's a federal ban in the works for TP-Link routers with support from not just one but several federal departments and agencies. If successful, we could see networking devices from the company ...

What would a Tesla be without controversy and split opinions? The Tesla Model Y’s midcycle refresh brought significant enough changes to earn it a spot in our 2026 SUV of the Year competition. The ...

TP-Link is warning of two command injection vulnerabilities in Omada gateway devices that could be exploited to execute arbitrary OS commands. Omada gateways are marketed as full-stack solutions ...

American Vogue’s August 2025 issue has been making headlines — and not only for its cover featuring actor Anne Hathaway, who is back in the limelight as she films “The Devil Wears Prada” sequel. What ...

The US is conducting a criminal antitrust investigation into pricing strategies by TP-Link Systems Inc., a California-based router maker with links to China whose equipment now dominates the American ...

TP-Link is one of the most popular router manufacturers in the US, but the company is facing a potential ban due to security concerns about its links to China. A December report from The Wall Street ...

ESSEX, Conn.--(BUSINESS WIRE)--Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat ...